Mapping the Tumor 2.0
Havas Lynx
[02.24.066]
More Info
In an evolving oncology landscape, biomarker-driven treatment decisions are crucial.
In 2021 there were over 17 updates to clinical guidelines for breast, prostate and ovarian cancer. Oncologists would have to read around 178 articles daily to keep up.
With best practice always changing, time-poor HCP’s face information overload. As a result, 52% of community oncologists don’t use biomarker testing to inform treatment.
We created ‘Mapping the Tumor’ as a solution to simplify this complex data by using a straightforward metaphor to highlight biomarker testing’s importance, better educate HCPs, and get patients the personalised treatment they need.
- Client Astra Zeneca , Merck
- Ad Agency Havas Lynx
- Creative Director Sam Sargen , Richard Hague , John Mcpartland
- Copywriter Chris Will
- Chief Executive Officer Claire Knapp
- Chief Medical Officer Vernon Bainton
- Chief Creative Officer Alex Okada
- Creative Director Sam Sargent
- Creative Director Richard Hague
- Executive Creative Director Chris Wellard
- Senior Creative Kate Phillips
- Senior Planner Mikey Weal
- Copywriter Chris Will
- Head of Copy Dave Eyre
- Chief Strategy Officer Andrew Gardner
- Executive Producer Jeff Corrin
- Head of Studios Chris Davies
- Creative Director John McPartland
- Account Manager Alex Taylor
- Account Director Ellen Shaw
- Medical Writer Mairiosa Hall
- Medical Writer Nur Pirbhai
- Account Manager Matt Digby
- Copywriting Chris Will
Related Work
[02.24.222]
1/3
[02.24.221]
1/4
[02.24.191]
1/4
[02.24.178]
1/3
[02.24.151]
1/2
[02.24.073]
1/5
[02.24.095]
1/3
[1.24.103]
1/5
[1.24.027]
1/3
[01.24.070]
1/2
More: Astra Zeneca, Merck
[4.19.089]
1/2
[BDA.15.195]
1/1
[2.12.025]
1/1
[BIL.07.011]
1/1
